cytoplasmic loop, Brain Res. Mol. Brain Res. 90 (2001) 110-117, https://doi.org/10.1016/s0169-328x(01)00090-0

[14] W. Deraredj Nadim, S. Chaumont-Dubel, F. Madouri, L. Cobret, M.-L. De Tauzia, P. Zajdel, H. Bénédetti, P. Marin, S. Morisset-Lopez, Physical interaction between neurofibromin and serotonin 5-HT6 receptors promotes receptor constitutive activity, Proc. Natl. Acad. Sci. U.S.A. 113 (2016) 12310-12315, https://doi.org/10.1073/pnas.1600914113.

[15] F. Duhr, P. Déléris, F. Raynaud, M. Séveno, S. Morisset-Lopez, C. Mannoury la Cour, M.J. Millan, J. Bockaert, P. Marin, S. Chaumont-Dubel, Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth, Nat. Chem. Biol. 10 (2014) 590-597, https://doi.org/10.1038/nchembio.1547.

[16] M. Jacobshagen, M. Niquille, S. Chaumont-Dubel, P. Marin, A. Dayer, The serotonin 6 receptor controls neuronal migration during corticogenesis via a ligand-independent Cdk5-dependent mechanism, Development 141 (2014) 3370-3377, https://doi.org/10.1242/dev.108043.

[17] A.B. Allnutt, A.K. Waters, S. Kesari, V.M. Yenugonda, Physiological and pathological roles of Cdk5: potential directions for therapeutic targeting in neurodegenerative disease, ACS Chem. Neurosci. 11 (2020) 1218-1230, https://doi.org/10.1021/acschemneuroc.0c0096.

[18] A.M. Bokare, A.K. Praveenkumar, M. Bhonde, Y. Nayak, R. Pal, R. Goel, 5-HT6 receptor agonist and antagonist against β-amyloid-peptide-induced neurotoxicity in PC-12 cells, Neurochem. Res. 42 (2017) 1571-1579, https://doi.org/10.1007/s11064-017-2217-9.

[19] P. Pyka, W. Haberek, M. Więczek, E. Szymanska, W. Ali, A. Cios, M. Jastrzębska-Więsek, G. Satala, S. Podlewska, S. Di Giacomo, A. Di Sotto, S. Garbo, T. Karcz, C. Lambona, F. Marocco, G. Latacz, S. Sudol-Talaj, B. Mordyl, M. Gluch-Lutwin, A. Siwek, K. Czarnota-Lydka, D. Gogola, A. Olejarz-Maciej, N. Wilczyńska-Zawal, E. Honkisz-Orzechowska, M. Starek, M. Dąbrowska, K. Kucwaj-Brysz, R. Fioravanti, M.J. Nasim, P. Hittinger, A. Partyka, A. Wesołowska, C. Battistelli, C. Zwergel, J. Handzlik, First-in-Class selenium-containing potent serotonin receptor 5-HT6 agents with a beneficial neuroprotective profile against Alzheimer's disease, J. Med. Chem. (2024), https://doi.org/10.1021/acs.jmedchem.3c02148.

[20] D. Vanda, V. Canale, S. Chaumont-Dubel, R. Kurczab, G. Satala, P. Koczurkiewicz-Adamczyk, M. Krawczyk, W. Pietruś, K. Blicharz, E. Pekala, A.J. Bojarski, P. Popik, P. Marin, M. Soural, P. Zajdel, Imidazopyridine-based 5-HT6 receptor neutral antagonists: impact of N1-benzyl and N1-phenylsulfonyl fragments on different receptor conformational states, J. Med. Chem. 64 (2019) 1180-1196, https://doi.org/10.1021/acs.jmedchem.0c02009.

[21] V. Canale, W. Trybała, S. Chaumont-Dubel, P. Koczurkiewicz-Adamczyk, G. Satala, O. Bento, K. Blicharz-Futera, X. Bantreil, E. Pekala, A.J. Bojarski, F. Lamaty, P. Marin, P. Zajdel, 1-(Arylsulfonyl-isodinol-2-yl)piperazines as 5-HT6R antagonists: mechanochemical synthesis, in vitro pharmacological properties and glioprotective activity, Biomolecules 13 (2022) 12, https://doi.org/10.3390/biom1301002.

[22] K. Grychowska, S. Chaumont-Dubel, R. Kurczab, P. Koczurkiewicz, C. Deville, M. Krawczyk, W. Pietruś, G. Satala, S. Buda, K. Piska, M. Drop, X. Bantreil, F. Lamaty, E. Pekala, A.J. Bojarski, P. Popik, P. Marin, P. Zajdel, Dual 5-HT6 and D3 receptor antagonists in a group of 1 H-Pyrrolo[3,2-c]quinolines with neuroprotective and proconvulsive activity, ACS Chem. Neurosci. (2019), https://doi.org/10.1021/acschemneuro.8b00618.

[23] K. Grychowska, U. López-Sánchez, M. Vitalis, G. Canet, G. Satala, A. Olejarz-Maciej, J. Gołbiowska, R. Kurczab, W. Pietruś, M. Kubacka, C. Moreau, M. Walczak, K. Blicharz-Futera, O. Bento, X. Bantreil, G. Subra, A.J. Bojarski, F. Lamaty, C. Becamel, C. Zussy, S. Chaumont-Dubel, P. Popik, H. Nury, P. Marin, L. Givalois, P. Zajdel, Superiority of the triple-acting 5-HT6R/5-HT3R antagonist and MAO-B reversible inhibitor PZ-1922 over 5-HT6R antagonist intepiridine in alleviation of cognitive deficits in rats, J. Med. Chem. 66 (2023) 14928-14947, https://doi.org/10.1021/acs.jmedchem.3c01482.

[24] P. Zajdel, M. Drop, V. Canale, M. Pawłowski, G. Satala, A. Bojarski, G. Subra, J. Martinez, X. Bantreil, F. Lamaty, P.-Y. Martin, C. Courteix, S. Chaumont-Dubel, P. Marin, Arylsulfonamides of 2-arylpyrrole-3-carboxamides for the treatment of cns disorders, WO2020117075A1 (2020). https://patents.google.com/patent/WO2020117075A1/en. (Accessed 14 October 2020).

[25] M. Drop, V. Canale, S. Chaumont-Dubel, R. Kurczab, G. Satala, X. Bantreil, M. Walczak, P. Koczurkiewicz-Adamczyk, G. Latacz, A. Gwizdak, M. Krawczyk, J. Gołbiowska, K. Grychowska, A.J. Bojarski, A. Nikiforuk, G. Subra, J. Martinez, M. Pawłowski, P. Popik, P. Marin, F. Lamaty, P. Zajdel, 2-Phenyl-1H-pyrrole-3-carboxamide as a new scaffold for developing 5-HT6 receptor inverse agonists with cognition-enhancing activity, ACS Chem. Neurosci. 12 (2021) 1228-1240, https://doi.org/10.1021/acschemneuroc.1c00061.

[26] P.-Y. Martin, S. Doly, A.M. Hamieh, E. Chapuy, V. Canale, M. Drop, S. Chaumont-Dubel, X. Bantreil, F. Lamaty, A.J. Bojarski, P. Zajdel, A. Eschalier, P. Marin, C. Courteix, mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment, Prog. Neurobiol. 193 (2020) 101846, https://doi.org/10.1016/j.pneurobio.2020.101846.

[27] B. Benhamú, M. Martín-Fontecha, H. Vázquez-Villa, L. Pardo, M.L. López-Rodríguez, Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease, J. Med. Chem. 57 (2014) 7160-7181, https://doi.org/10.1021/jm5003952.

[28] V. Canale, K. Grychowska, R. Kurczab, M. Ryng, A.R. Keeri, G. Satala, A. Olejarz-Maciej, P. Koczurkiewicz, M. Drop, K. Blicharz, K. Piska, E. Pekala, P. Janiszewska, M. Krawczyk, M. Walczak, S. Chaumont-Dubel, A.J. Bojarski, P. Marin, P. Popik, P. Zajdel, A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties, Eur. J. Med. Chem. 208 (2020) 112765, https://doi.org/10.1016/j.ejmech.2020.112765.

[29] K. Grychowska, G. Satala, T. Kos, A. Partyka, E. Colacino, S. Chaumont-Dubel, X. Bantreil, A. Wesołowska, M. Pawłowski, J. Martinez, P. Marin, G. Subra, A. J. Bojarski, F. Lamaty, P. Popik, P. Zajdel, Novel 1H-Pyrrolo[3,2-c]quinoline based 5-HT6 receptor antagonists with potential application for the treatment of cognitive disorders associated with Alzheimer's disease, ACS Chem. Neurosci. 7 (2016) 972-983, https://doi.org/10.1021/acschemneuro.6b00090.

[30] D. Vanda, M. Soural, V. Canale, S. Chaumont-Dubel, G. Satala, T. Kos, P. Funk, V. Fülöpová, B. Lemrová, P. Koczurkiewicz, E. Pekala, A.J. Bojarski, P. Popik, P. Marin, P. Zajdel, Novel non-sulfonamide 5-HT6 receptor partial inverse agonist in a group of imidazo[4,5-b]pyridines with cognition enhancing properties, Eur. J. Med. Chem. 144 (2018) 716-729, https://doi.org/10.1016/j.ejmech.2017.12.053.

[31] L.I. Jiang, J. Collins, R. Davis, K.-M. Lin, D. DeCamp, T. Roach, R. Hsueh, R. A. Rebres, E.M. Ross, R. Taussig, I. Fraser, P.C. Sternweis, Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/ G13 pathway, J. Biol. Chem. 282 (2007) 10576-10584, https://doi.org/10.1074/jbc.M609695200.

[32] L. He, Q. Zhao, J. Qi, Y. Wang, W. Han, Z. Chen, Y. Cong, S. Wang, Structural insights into constitutive activity of 5-HT6 receptor, Proc. Natl. Acad. Sci. U. S. A. 120 (2023) e2209917120, https://doi.org/10.1073/pnas.2209917120.

[33] V. Isberg, C. de Graaf, A. Bortolato, V. Cherezov, V. Katritch, F.H. Marshall, S. Mordalski, J.-P. Pin, R.C. Stevens, G. Vriend, D.E. Gloriam, Generic GPCR residue numbers - aligning topology maps while minding the gaps, Trends Pharmacol. Sci. 36 (2015) 22-31, https://doi.org/10.1016/j.tips.2014.11.001.

[34] W. Pietruś, R. Kurczab, R. Kafel, E. Machalska, J. Kalinowska-Tlućik, A. Hogendorf, M. Zylewski, M. Baranska, A. Bojarski, How can fluorine directly and indirectly affect the hydrogen bonding in molecular systems? - a case study for monofluoroanilines, Spectrochim. Acta Biol. Biomol. Spectrosc. 252 (2021) 119536, https://doi.org/10.1016/j.saa.2021.119536.

[35] K. Czarnota-Lydka, S. Sudol-Talaj, K. Kucwaj-Brysz, R. Kurczab, G. Satala, M. de Canda, F. Samarelli, C.D. Altomare, A. Adrocii, A. BarROSSA, E. Zesławska, M. Gluch-Lutwin, B. Mordyl, M. Kubacka, N. Wilczyńska-Zawal, M. Jastrzębska-Więsek, A. Partyka, N. Khan, M. Więczek, W. Nitek, E. Honkisz-Orzechowska, G. Latacz, A. Wesołowska, A. Carrieri, J. Handzlik, Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease, Eur. J. Med. Chem. 259 (2023) 115695, https://doi.org/10.1016/j.ejmech.2023.115695.

[36] T.T. Wager, X. Hou, P.R. Verhoest, A. Villalobos, Central nervous system multiparameter optimization desirability: application in drug discovery, ACS Chem. Neurosci. 7 (2016) 767-775, https://doi.org/10.1021/acschemneuro.6b00029.

[37] A.J. Lesiak, M. Brodsky, N. Cohena, A.G. Croicu, J.F. Neumaier, Restoration of physiological expression of 5-HT6 receptor into the primary cilia of null mutant neurons lengthens both primary cilia and dendrites, Mol. Pharmacol. 94 (1998) 731-742, https://doi.org/10.1124/mol.117.111583.

[38] W.D. Hirst, G.W. Price, M. Rattray, G.P. Wilkin, Identification of 5-hydroxytryptamine receptors positively coupled to adenylate cyclase in rat cultured astrocytes, Br. J. Pharmacol. 120 (1997) 509-515, https://doi.org/10.1038/sj.bp.0700921.

[39] N.J. Allen, D.A. Lyons, Glia as architects of central nervous system formation and function, Science 362 (2018) 181-185, https://doi.org/10.1126/science.aat0473.

[40] R. Kurczab, V. Canale, G. Satala, P. Zajdel, A.J. Bojarski, Amino acid hot spots of halogen bonding: a combined theoretical and experimental case study of the 5-HT7 receptor, J. Med. Chem. 61 (2018) 8717-8733, https://doi.org/10.1021/acs.jmedchem.8b00828.

[41] Y. Cheng, W.H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol. 22 (1973) 3099-3108.

[42] H.C. Cheng, The power issue: determination of KB or Ki from IC50, J. Pharmacol. Toxicol. Methods 46 (2001) 61-71, https://doi.org/10.1016/S1056-8719(02)00166-1.

[43] S. Huang, P. Xu, D.-D. Shen, I.A. Simon, C. Mao, Y. Tan, H. Zhang, K. Harpsøe, H. Li, Y. Zhang, C. You, X. Yu, Y. Jiang, Y. Zhang, D.E. Gloriam, H.E. Xu, GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors, Mol. Cell 82 (2022) 2681-2695.e6, https://doi.org/10.1016/j.molcel.2022.05.031.

[44] wwPDB consortium, Protein Data Bank: the single global archive for 3D macromolecular structure data, Nucleic Acids Res. 47 (2019) D520-D528, https://doi.org/10.1093/nar/gky949.

[45] K.J. Bowers, E. Chow, H. Xu, R.O. Dror, M.P. Eastwood, B.A. Gregersen, J. L. Klepis, I. Kolossvary, M.A. Moraes, F.D. Sacerdoti, J.K. Salmon, Y. Shan, D. E. Shaw, Scalable algorithms for molecular dynamics simulations on commodity clusters, in: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, Association for Computing Machinery, New York, NY, USA, 2006, pp. 84-es, https://doi.org/10.1145/1188455.1188544.

[46] M.A. Lomize, I.D. Pogozheva, H. Joo, H.I. Mosberg, A.L. Lomize, OPM database and PPM web server: resources for positioning of proteins in membranes, Nucleic Acids Res. 40 (2012) D370-D376, https://doi.org/10.1093/nar/gkr703.

[47] J.K. Singh, A. Solanki, Comparative in-vitro intrinsic clearance of imipramine in multiple species liver microsomes: human, rat, mouse and dog, J. Drug Metabol. Toxicol. 3 (2012), https://doi.org/10.4172/2157-7609.1000126.